

GIM JOURNAL CLUB (23GRMR32)

Provided by Rutgers, Robert Wood Johnson Medical School, Department of Medicine, Division of General Internal Medicine

July Jama, Volume 328 Number 1-4
July LANCET, Volume 400, Number 10348

Clinical Academic Building – Room 2326, New Brunswick, NJ 08901

Thursday, August 18, 2022

8:00 – 9:00am

Dr. Carmen Shulman
Assisting Professor, Rutgers, Robert Wood Johnson Medical School

Objectives

At the conclusion of this activity, participants should be better able to:

- Implement new practice guidelines in General Internal Medicine.
- Recommend new treatments, procedures and medications, affecting the practice of General Internal Medicine.
- Manage common problems seen in General Internal Medicine.
- Build consensus within the group to address common problems in General Internal Medicine.

Target Audience

This activity is designed for physicians with the specialty of General Internal Medicine.

Accreditation



In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Physicians: Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Declarations

Dr. Carmen Shulman has no relevant financial relationship(s) with ineligible companies to disclose.

Speakers are required to disclose discussion of off-label/investigational uses of commercial products/devices in their presentation. These disclosures will be made to the audience at the time of the activity.

Planning Committee:

Dr. Carson has the following relevant financial relationships with ineligible companies: Member, Advisory Board: Cerus; Consultant: Biogen; Grant/Research Support: Olatec, Synavir. All of the relevant financial relationships listed have been mitigated. Drs. Schneiderman (content reviewer), Sonnenberg and Steinberg have no relevant financial relationships with ineligible companies to disclose.